Achieving “Zero” Defects for Visible Particles in Injectables

References

1. Parenteral Drug Association. PDA Survey: 2014 Visual Inspection. PDA: Bethesda, Md., 2015.
2. Parenteral Drug Association. PDA Survey: 2015 Particulate Matter in Difficult to Inspect Parenterals. PDA: Bethesda, Md., 2016.
3. 1. Langille S. E.

   Particulate Matter in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2013, 67 (3), 186–200.

   OpenUrlPubMed
4. 1. Davis K.,
   2. et al

   . Recommendations for Testing, Evaluation, and Control of Particulates from Single-Use Process Equipment; Bio-Process Systems Alliance (BPSA): Washington, DC, 2014.
5. ECA Visual Inspection Group. Good Practice Paper: Visual Inspection of Medicinal Products for Parenteral Use; ECA Foundation: Heidelberg, 2014.
6. 1. Borchert S.,
   2. et al

   . Particulate Matter in Parenteral Products: A Review. PDA J. Pharm. Sci. Technol. 1986, 40 (5), 212–237.
7. 1. Kim J.,
   2. Schildt D.,
   3. et al

   . Investigation of Foreign-Particle Contamination: Practical Application of FT-IR, Raman, and SEM-EDS Technologies. BioProcess International 2016, 14 (8).
8. 1. Mathonet S.,
   2. et al

   . A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2016, 70 (4), 392–408.
9. 1. Shabushnig J.,
   2. et al

   . A Proposed Working Standard for Validation of Particulate Inspection in Sterile Solutions. Presented at PDA Annual Meeting, Philadelphia, Pa., 1995.
10. 1. Aldrich S.,
    2. Cherris R.,
    3. Shabushnig J.

    Visual Inspection and Particulate Control. DHI Publishing: Scottsdale, Ar., 2016. www.pda.org/bookstore.